Alnylam Pharmaceuticals (ALNY) Cash from Investing Activities (2009 - 2026)

Alnylam Pharmaceuticals (ALNY) has 18 years of Cash from Investing Activities data on file, last reported at -$363.5 million in Q2 2026.

• Quarterly Cash from Investing Activities fell 157.08% year-over-year to -$363.5 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $74.9 million (up 167.65% YoY) and the FY2025 annual result came in at $436.3 million, up 473.44% from the prior year.
• Cash from Investing Activities slipped to -$363.5 million in Q2 2026, from -$25.5 million in the prior quarter.
• In the past five years, Cash from Investing Activities ranged from a high of $501.1 million in Q3 2025 to a low of -$363.5 million in Q2 2026.
• A 5-year average of -$13.1 million and a median of -$33.7 million in 2024 frame the typical range for Cash from Investing Activities.
• The widest YoY moves for Cash from Investing Activities: up 1756.55% in 2025, down 516.56% in 2025.
• Tracing ALNY's Cash from Investing Activities over 5 years: stood at -$139.9 million in 2022, then slumped by 72.01% to -$240.7 million in 2023, then jumped by 78.01% to -$52.9 million in 2024, then advanced by 29.76% to -$37.2 million in 2025, then plunged by 877.93% to -$363.5 million in 2026.
• The last three Cash from Investing Activities figures came in at -$363.5 million (Q2 2026), -$25.5 million (Q1 2026), and -$37.2 million (Q4 2025), per Business Quant data.